Back

GH Research resolves FDA hold on GH001, plans phase 3 trial for 2026

Verifying
  • GH Research PLC resolved the FDA clinical hold affecting its GH001 application.
  • 2026 is the expected start year for GH001’s pivotal phase 3 trial.
  • GH001 is an investigational treatment targeting resistant depression.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.